Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
|Articles|March 13, 1996

Positron offering raises $3 million

PET developer Positron of Houston last week completed a privatestock offering that solves a cash-flow problem that has doggedthe firm since late last year (SCAN 2/28/96). Positron issuedconvertible preferred stock and purchase warrants to raise

PET developer Positron of Houston last week completed a private

stock offering that solves a cash-flow problem that has dogged

the firm since late last year (SCAN 2/28/96). Positron issued

convertible preferred stock and purchase warrants to raise net

proceeds of $3 million, which will be used for working capital,

to make payments on PET components, and to increase its tangible

assets. The offering enabled Positron to meet NASDAQ's tangible

net asset requirements and maintain the company's listing on the

exchange.

Related to this article

Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.